Clinical Trial Update: Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612 [Phase 3]

View source ↗

Summary

Phase 3 study by GlaxoSmithKline Biologicals evaluating non-inferiority and immunogenicity of Meningococcal Vaccine 134612 has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Meningococcal Vaccine 134612

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2012-05-22